Limited Transmission of Drug-Resistant HIV Type 1 in 100 Swedish Newly Detected and Drug-Naive Patients Infected with Subtypes A, B, C, D, G, U, and CRF01_AE

AIDS Research and Human Retroviruses

Volumn 19, Issue 11, 2003, Pages 989-997

  Maljkovic, Irina ^a,b   Wilbe, Karin ^a,b   Sölver, Ellen ^a   Alaeus, Annette ^c   Leitner, Thomas ^a,d  

^a SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^b KAROLINSKA INSTITUTE   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d LOS ALAMOS NATIONAL LABORATORY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; NEVIRAPINE; PROTEINASE; RNA DIRECTED DNA POLYMERASE; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; VIRUS ENZYME; VIRUS RNA; ZALCITABINE;

AMINO ACID SEQUENCE; BLOOD ANALYSIS; CONTROLLED STUDY; FEMALE; GENE MUTATION; GENE SEQUENCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HOMOSEXUALITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN IMMUNODEFICIENCY VIRUS PREVALENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; NONHUMAN; OUTPATIENT DEPARTMENT; POPULATION RESEARCH; PRIORITY JOURNAL; RANDOMIZATION; REVIEW; RNA EXTRACTION; SWEDEN; VIRUS CLASSIFICATION; VIRUS MUTATION; VIRUS TRANSMISSION;

ANTI-HIV AGENTS; DRUG RESISTANCE, VIRAL; GENOTYPE; HIV INFECTIONS; HIV PROTEASE; HIV-1; HIV-1 REVERSE TRANSCRIPTASE; HUMANS; MALE; MUTATION; REVERSE TRANSCRIPTASE INHIBITORS; SEQUENCE ANALYSIS, DNA; SWEDEN;

EID: 0242294762     PISSN: 08892229     EISSN: None     Source Type: Journal    
DOI: 10.1089/088922203322588341     Document Type: Review

References (55)

1. Carpenter CC, Fischl MA, Hammer SM, et al: Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society-USA Panel. JAMA 1998;280: 78-86.
2. Palella FJ Jr, Delaney KM, Moorman AC, et al.: Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators. N Engl J Med 1998;338:853-860.
3. Larder BA and Kemp SD: Multiple mutations in HIV-1 reverse transcriptase confer high-level resistance to zidovudine (AZT). Science 1989;246:1155-1158.
4. Molla A, Korneyeva M, Gao Q, et al.: Ordered accumulation of mutations in HIV protease confers resistance to ritonavir. Nat Med 1996;2:760-766.
5. Wainberg MA and Friedland G: Public health implications of antiretroviral therapy and HIV drug resistance. JAMA 1998;279: 1977-1983.
6. Condra JH, Schleif WA, Blahy OM, et al.: In vivo emergence of HIV-1 variants resistant to multiple protease inhibitors. Nature 1995;374:569-571.
7. Feinberg M: Hidden dangers of incompletely suppressive antiretroviral therapy. Lancet 1997;349:1408-1409.
8. Hecht FM, Grant RM, Petropoulos CJ, et al.: Sexual transmission of an HIV-1 variant resistant to multiple reverse-transcriptase and protease inhibitors. N Engl J Med 1998;339:307-311.
9. Boden D, Hurley A, Zhang L, et al.: HIV-1 drug resistance in newly infected individuals. JAMA 1999;282:1135-1141.
10. Little SJ, Daar ES, D'Aquila RT, et al.: Reduced antiretroviral drug susceptibility among patients with primary HIV infection. JAMA 1999;282:1142-1149.
11. Yerly S, Kaiser L, Race E, Bru JP, Clavel F, and Perrin L: Transmission of antiretroviral-drug-resistant HIV-1 variants. Lancet 1999;354:729-733.
12. UK Collaborative Group on Monitoring the Transmission of HIV Drug Resistance: Analysis of prevalence of HIV-1 drug resistance in primary infections in the United Kingdom. BMJ 2001;322:1087-1088.
13. Little SJ, Holte S, Routy J-P, et al.: Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med 2002;347:385-394.
14. Salomon H, Wainberg MA, Brenner B, et al.: Prevalence of HIV-1 resistant to antiretroviral drugs in 81 individuals newly infected by sexual contact or injecting drug use. Investigators of the Quebec Primary Infection Study. AIDS 2000;14:F17-23.
15. Wegner SA, Brodine SK, Mascola JR, et al.: Prevalence of genotypic and phenotypic resistance to anti-retroviral drugs in a cohort of therapy-naive HIV-1 infected US military personnel. AIDS 2000;14:1009-1115.
16. Cesaire R, Dos Santos G, Abel S, Bera O, Sobesky G, and Cabie A: Drug resistance mutations among HIV-1 strains from antiretroviral-naive patients in Martinique, French West Indies. J Acquir Immune Defic Syndr 1999;22:401-405.
17. Geretti AM, Smith M, Osner N, et al.: Prevalence of antiretroviral resistance in a South London cohort of treatment-naive HIV-1-infected patients. AIDS 2001;15:1082-1084.
18. Nannini EC, Han X, O'Brien WA, and Arduino RC: Genotypic HIV-1 drug resistance testing in antiretroviral-naive subjects in Houston, Texas. J Acquir Immune Defic Syndr 2002;29:317-319.
19. Briones C, Perez-Olmeda M, Rodriguez C, del Romero J, Hertogs K, and Soriano V: Primary genotypic and phenotypic HIV-1 drug resistance in recent seroconverters in Madrid. J Acquir Immune Defic Syndr 2001;26:145-150.
20. Verbiest W, Brown S, Cohen C, et al.: Prevalence of HIV-1 drug resistance in antiretroviral-naive patients: A prospective study. AIDS 2001;15:647-650.
21. Re MC, Monari P, Bon I, et al.: Analysis of HIV-1 drug resistant mutations by line probe assay and direct sequencing in a cohort of therapy naive HIV-1 infected Italian patients. BMC Microbiol 2001;1:30.
22. Duwe S, Brunn M, Altmann D, et al.: Frequency of genotypic and phenotypic drug-resistant HIV-1 among therapy-naive patients of the German Seroconverter Study. J Acquir Immune Defic Syndr 2001;26:266-273.
23. Brenner B, Wainberg MA, Salomon H, et al.: Resistance to antiretroviral drugs in patients with primary HIV-1 infection. Investigators of the Quebec Primary Infection Study. Int J Antimicrob Agents 2000;16:429-434.
24. Najera I, Holguin A, Quinones-Mateu ME, et al.: Pol gene quasi-species of human immunodeficiency virus: Mutations associated with drug resistance in virus from patients undergoing no drug therapy. J Virol 1995;69:23-31.
25. Gonzales MJ, Machekano RN, and Shafer RW: Human immunodeficiency virus type 1 reverse-transcriptase and protease subtypes: Classification, amino acid mutation patterns, and prevalence in a northern California clinic-based population. J Infect Dis 2001;184:998-1006.
26. Becker-Pergola G, Kataaha P, Johnston-Dow L, Fung S, Jackson JB, and Eshleman SH: Analysis of HIV type 1 protease and reverse transcriptase in antiretroviral drug-naive Ugandan adults. AIDS Res Hum Retroviruses 2000;16:807-813.
27. Harrigan PR, Montaner JS, Wegner SA, et al.: World-wide variation in HIV-1 phenotypic susceptibility in untreated individuals: Biologically relevant values for resistance testing. AIDS 2001;15:1671-1677.
28. Vergne L, Peeters M, Mpoudi-Ngole E, et al.: Genetic diversity of protease and reverse transcriptase sequences in non-subtype-B human immunodeficiency virus type 1 strains: Evidence of many minor drug resistance mutations in treatment-naive patients. J Clin Microbiol 2000;38:3919-3925.
29. Descamps D, Calvez V, Izopet J, et al.: Prevalence of resistance mutations in antiretroviral-naive chronically HIV-infected patients in 1998: A French nationwide study. AIDS 2001;15:1777-1782.
30. Pieniazek D, Rayfield M, Hu DJ, et al.: Protease sequences from HIV-1 group M subtypes A-H reveal distinct amino acid mutation patterns associated with protease resistance in protease inhibitor-naive individuals worldwide. HIV Variant Working Group. AIDS 2000;14:1489-1495.
31. Alaeus A, Leitner T, Lidman K, and Albert J: Most HIV-1 genetic subtypes have entered Sweden. AIDS 1997;11:199-202.
32. Birk M and Sönnerborg A: Variations in HIV-1 pol gene associated with reduced sensitivity to antiretroviral drugs in treatment-naive patients. AIDS 1998;12:2369-2375.
33. Rambaut A: SeAl: Sequence alignment program, v1.d1. University of Oxford, UK, 1995.
34. Kuiken C, Foley B, Hahn B, et al.: HIV Sequence Compendium 2000. Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, Los Alamos, NM, 2000.
35. Swofford D: PAUP*, v4.0b10. Sinauer Associates, Sunderland, MA, 2002.
36. Felsenstein J: PHYLIP: Phylogeny Inference Package, 3.52c ed. University of Washington, Seattle, WA, 1993.
37. Leitner T, Escanilla D, Franzen C, Uhlen M, and Albert J: Accurate reconstruction of a known HIV-1 transmission history by phylogenetic tree analysis. Proc Natl Acad Sci USA 1996;93:10864-10869.
38. Robertson DL, Anderson JP, Bradac JA, et al: HIV-1 nomenclature proposal. Science 2000;288:55-56.
39. Kuiken C and Leitner T. HIV-1 subtyping. In: Computational Analysis of HIV Molecular Sequences (Rodrigues A and Learn G, eds.). Kluwer Academic Publishers, Boston, 2001, pp. 27-53.
40. Ray S: SimPlot, v2.5. Johns Hopkins University, Baltimore, MD, 1999.
41. Hirsch MS, Brun-Vezinet F, D'Aquila RT, et al.: Antiretroviral drug resistance testing in adult HIV-1 infection. Recommendations of an International AIDS Society - USA Panel. JAMA 2000; 283:2417-2426.
42. International AIDS Society-USA Resistance Testing Panel and HIV InSite: Antiretroviral resistance mutations (revised April 2001). HIV Clin Trials 2001;2:346-355.
43. Korber B and Myers G: Signature pattern analysis: A method for assessing viral sequence relatedness. AIDS Res Hum Retroviruses 1992;8:1549-1560.
44. Cornelissen M, van den Burg R, Zorgdrager F, Lukashov V, and Goudsmit J: pol gene diversity of five human immunodeficiency virus type 1 subtypes: Evidence for naturally occurring mutations that contribute to drug resistance, limited recombination patterns, and common ancestry for subtypes B and D. J Virol 1997;71:6348-6358.
45. Jeeninga RE, Keulen W, Boucher C, Sanders RW, and Berkhout B: Evolution of AZT resistance in HIV-1: The 41-70 intermediate that is not observed in vivo has a replication defect. Virology 2001;283:294-305.
46. Back NK, Nijhuis M, Keulen W, et al.: Reduced replication of 3TC-resistant HIV-1 variants in primary cells due to a processivity defect of the reverse transcriptase enzyme. EMBO J 1996;15:4040-4049.
47. Magiorkinis E, Paraskevis D, Magiorkinis G, et al.: Mutations associated with genotypic resistance to antiretroviral therapy in treatment naive HIV-1 infected patients in Greece. Virus Res 2002;85:109-115.
48. Perno CF, Cozzi-Lepri A, Balotta C, et al.: Low prevalence of primary mutations associated with drug resistance in antiviral-naive patients at therapy initiation. AIDS 2002;16:619-624.
49. Yahi N, Fantini J, Tourres C, Tivoli N, Koch N, and Tamalet C: Use of drug resistance sequence data for the systematic detection of non-B human immunodeficiency virus type 1 (HIV-1) subtypes: How to create a sentinel site for monitoring the genetic diversity of HIV-1 at a country scale. J Infect Dis 2001;183:1311-1317.
50. Kozal MJ, Shah N, Shen N, et al.: Extensive polymorphisms observed in HIV-1 clade B protease gene using high-density oligonucleotide arrays. Nat Med 1996;2:753-759.
51. Alexander CS, Montessori V, Wynhoven B, et al.: Prevalence and response to antiretroviral therapy of non-B subtypes of HIV in antiretroviral-naive individuals in British Columbia. Antiviral Ther 2002;1:31-35.
52. Brindeiro PA, Brindeiro RM, Mortensen C, et al.: Testing genotypic and phenotypic resistance in human immunodeficiency virus type 1 isolates of clade B and other clades from children failing antiretroviral therapy. J Clin Microbiol 2002;40:4512-4519.
53. Grossman Z, Vardinon N, Chemtob D, et al.: Genotypic variation of HIV-1 reverse transcriptase and protease: Comparative analysis of clade C and clade B. AIDS 2001;15:1453-1460.
54. Caride E, Brindeiro RM, Hertogs K, et al.: Drug-resistent reverse transcriptase genotyping and phenotyping of B and non-B subtypes (F and A) of human immunodeficiency virus type I found in Brazilian patients failing HAART. Virology 2000;275:107-115.
55. Brenner B, Turner D, Oliveira M, et al.: A V106M mutation in HIV-1 clade C viruses exposed to efavirnez confers cross-resistance to non-nucleoside reverse transcriptase inhibitors. AIDS 2003;17:F1-F5.